Davie, Alison, Sory Traoré, Massimo Giovannitti, Giuseppe Pompilio, Mark Lambton, Esra Cakar, and Anuja Chatterjee. “Cost-Effectiveness Analysis of Abemaciclib With Endocrine Therapy (ET) Versus ET Alone for HR+, HER2−, Node-Positive, High-Risk Early Breast Cancer in Italy”. Global and Regional Health Technology Assessment 10, no. 1 (September 28, 2023): 62–69. Accessed July 3, 2024. https://journals.aboutscience.eu/index.php/grhta/article/view/2561.